Life Science

Big Changes in Preferred Provider Status

AmeriStart - USA Sales and Marketing - Big Changes in Preferred Provider StatusThose of you in the clinical research business will be interested to
see this article:

Pfizer is reducing the number of preferred providers it works with from Seventeen (17) to TWO (2).

This may not be a trend just yet, but I have read other articles that indicate other Big Pharma's are doing similar strategies.

If so, it means that this target market (Big Pharma) will be harder and harder to penetrate, and may actually be off-limits to smaller CROs and CSOs due simply to the length of time required to get on the preferred provider list, if its possible at all.

This is yet another indication that "the big companies are bigger and the small companies get slaughtered." 

New Molecular Entities approved by FDA

I thought you would be interested in this information...

In 2010, 23 New Molecular Entities (NMEs) were submitted to the FDA.

(This is the lowest number of NME applications, except in 2002, in over 15 years.)

Only 21 of these NMEs were approved.

Please click here to view the FDA's 2010 NMEs Comparison Chart.

A special thanks to my friend Sudhakar Bangera for sending this information to me.

2011 CRO Market Update -- Major Shifts Ahead

AmeriStart - Growing Your CROThe market for CRO services has shifted dramatically over the last 12 to 18 months.

But don't take it from me.... 

Sign up here to hear it from the senior analyst at Frost and Sullivan:

Specialize to Succeed

Find A NicheWant to know the #1 secret to success in business?  Read this great article in the USA Today, "Find a Niche" by Rhonda Abrams... or just let me tell you in my own words: "Pick-A-Niche". 

Here's the key in Rhonda's own words: "Specialists succeed"

How to Lose The Deal (Part 3): Failure to Ask Difficult Questions

Let's get straight to the point.  Customers want to do business with vendors (and sales people) who are truly professionals in their chosen field. They actually need your help in solving difficult business problems. And today's busy prospects have lots of problems to deal with and little time to do it.  

Selling to a Moving Target

Business to Business SalesIt's tough to sell anything if you don't know the name of the buyer.  That's been the problem with Business to Business sales... "prospect databases" are hard to find and are rarely accurate.  People move around and change jobs so rapidly that yesterday's prospects are today's wrong numbers.

Are you High and Right?

If you've read any of our other blog posts, you know by now that the key to Success in America lies in being unique and highly differentiated from your competition.

I now see that we were wrong. 

Its great to be unique and different.  In fact, its absolutely necessary.  But that in itself is not enough.  We were missing one more key ingredient -- what Guy Kawasaki called "being high and to the right."

You see, being different is only one dimension of success.  The other...?

SNAP Selling

Jill Konrath - Snap SellingJill Konrath has done it again.

Her new book, SNAP Selling, hits the nail on the head.  It explains in detail what all of us selling products or services in the USA have been experiencing, and why.  Prospects never answer their phone, voice mails are never returned, e-mails are deleted, appointments are harder and harder to get, and when you get them, they are shorter and shorter.

Your Most Effective Business Tool

AmeriStart - Your Most Effective Business Tool

Imagine what you could do if you had a fully staffed office in America.

Imagine how much more productive you could be, how many more sales you could generate, or how many hours of time you could save.

Think about how impressive a USA telephone number, address, name would look on your web site or marketing materials.

Imagine how convenient it would be to have a sales, marketing and administrative team ready to help you with just a phone call or email.

 

Will Your CRO Survive the Pharma Consolidation of 2010?

AmeriStart - Shrinking markets for CROs means only the different will surviveViq Pervaaz, senior vice president, corporate transactions at Aon Consulting recently wrote an article for Outsourcing-Pharma.com that every CRO should read.  I'll summarize below, but here's a link to the full story: shrinking-market-for-cros

Mr. Pevaaz makes a good case that the consolidation in the Pharma industry is causing -- and will continue to cause -- pain within the research services market.  CROs, and the entire eco-system of service providers around them, will see a significant reduction in their pipeline of compounds (and customers). 

Syndicate content